FUS and myxoid liposarcoma: Zullow and colleagues demonstrated that the FUS–DDIT3 fusion protein drives the development of myxoid liposarcoma by sequestering the adipogenic transcription factor, CEBPB, and thus disrupting BAF-mediated gene targeting, leading to oncogenic gene transcription [25].